Keyword: Dynavax Technologies
Zombie biotech Dynavax will lose its chief scientific officer in December, but after a host of cuts, it won’t be looking for a new one.
Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.
The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B.
AstraZeneca moved the Dynavax-partnered TLR9 agonist into the trial in the belief it could improve time to loss of asthma control.
Get Wednesday's shot of biopharma news of note.
Dynavax has laid off 38% of its workforce in response to last year’s regulatory setback and its failure to find a partner.
The FDA has rejected the marketing application for Dynavax’s hepatitis B vaccine, prompting the company to start looking for a partner.
Small cap Dynavax bounced almost 20% on news that the FDA has requested information regarding its application for its hepatitis B vaccine.
During the Labor Day weekend, small cap Dynavax found it hard to relax after the FDA cancelled an advisory committee meeting for its experimental hep B vaccine, sending its shares plummeting before Friday’s close.
Three years after the FDA originally turned down Dynavax’s hep B vaccine Heplisav-B over safety concerns, the biotech faces more uncertainty as the regulator has pushed back its PDUFA date.